Kiniksa Pharmaceuticals International, plc filings document regulatory disclosures for a Nasdaq-listed biopharmaceutical company incorporated in England and Wales. Form 8-K reports cover operating results and financial condition, ARCALYST portfolio execution, investor presentations, and executive appointments or consulting arrangements.
Proxy materials cover annual meeting matters, director elections, executive compensation, shareholder voting procedures, and board governance. The filing record also identifies the company’s Class A ordinary shares, Nasdaq Global Select Market listing, and recurring disclosures tied to its commercial ARCALYST franchise and cardiovascular-focused development portfolio.
Kiniksa Pharmaceuticals International, plc director and CEO Sanj K. Patel reported a series of option exercises and related share sales in late April. He exercised options to acquire a total of 508,339 Class A Ordinary Shares at exercise prices of $10.36 and $30.93 per share, then sold the same number of shares in open-market transactions.
The reported sales occurred on April 28–30, 2026, at weighted average prices generally between $50.00 and about $54.23 per share, under a pre-arranged Rule 10b5-1 trading plan executed on October 31, 2025. After these transactions, filings show continued indirect ownership through family trusts, including 51,794, 109,795 and 76,174 Class A Ordinary Shares held by separate Patel family trusts, and remaining vested options for 48,565 shares at a $30.93 exercise price expiring in 2028.
Kiniksa Pharmaceuticals International, plc director Barry D. Quart executed an option exercise-and-sale transaction in Class A Ordinary Shares. He exercised options to acquire 13,099 shares at $14.33 per share and sold 13,099 shares at a weighted average price of $50.10 under a pre-arranged Rule 10b5-1 plan. The sale occurred in multiple broker-dealer trades between $50.00 and $50.725. After these transactions, he directly holds 12,546 shares and 13,237 remaining share options that are fully vested and exercisable, expiring on June 28, 2031.
Kiniksa Pharmaceuticals filed a Form 144 reporting proposed and recent sales of Class A Ordinary Shares. The report lists a broker payment for a cashless exercise on 04/28/2026 and discloses a prior sale of 7,278 shares by Sanj K Patel on 04/06/2026 for $363,949.
Kiniksa Pharmaceuticals International reported strong growth for the quarter ended March 31, 2026, driven by ARCALYST. Product revenue rose to $214.3 million, up from $137.8 million a year earlier, as more patients started treatment.
Net income increased to $22.6 million from $8.5 million, with diluted earnings per share rising to $0.27. Operating cash flow reached $50.2 million, and cash, cash equivalents and short-term investments totaled about $468.1 million, supporting ongoing R&D and commercialization.
The company continues to advance cardiovascular-focused programs, including KPL-387 in a Phase 2/3 trial for recurrent pericarditis and preclinical KPL-1161, while development of abiprubart has been discontinued as it explores strategic alternatives for that asset.
Kiniksa Pharmaceuticals International, plc reported strong first quarter 2026 results driven by ARCALYST. Net product revenue reached $214.3 million, representing 56% year-over-year growth, and total revenue was $214.3 million versus $137.8 million a year earlier. Net income rose to $22.6 million, up from $8.5 million, with diluted earnings per share increasing to $0.27 from $0.11.
The company raised its 2026 ARCALYST net sales guidance to a range of $930–$945 million, up from $900–$920 million, citing expanding adoption in recurrent pericarditis. Cash, cash equivalents, and short-term investments increased to $468.1 million as of March 31, 2026. Kiniksa highlighted portfolio progress, including Phase 2 KPL-387 recurrent pericarditis data expected in the second half of 2026 and initiation of a Phase 3 pivotal trial by year-end, as well as ongoing preclinical work on KPL-1161.
Kiniksa Pharmaceuticals International, plc is asking shareholders to vote on eight proposals at its 2026 Annual Meeting on May 29, 2026 at its London offices. Holders of Class A ordinary shares have one vote per share and Class B ordinary shares have ten votes per share as of the April 6, 2026 record date.
Proposals include re-electing three Class II directors until the 2029 meeting, appointing and ratifying PricewaterhouseCoopers LLP as UK statutory auditors and US independent registered public accounting firm, authorizing the Audit Committee to set PwC’s UK audit fees, and receiving the UK statutory annual report for 2025.
Shareholders are also being asked to approve, on an advisory basis, the UK Statutory Directors’ Remuneration Report, approve an updated UK Remuneration Policy governing director pay for up to three years, and cast a non-binding Say-on-Pay vote on compensation for named executive officers.
Kiniksa Pharmaceuticals International, plc chief accounting officer Michael R. Megna reported an open-market sale of 6,625 Class A Ordinary Shares at $46.69 per share on April 9, 2026. After this transaction, he directly holds 27,418 shares. The filing notes the sale was executed under a pre-arranged Rule 10b5-1 trading plan, indicating it was scheduled in advance rather than timed discretionarily.
Kiniksa Pharmaceuticals International, plc chief operating officer Moat Ross reported an open-market sale of 1,703 Class A Ordinary Shares on April 9, 2026 at $46.69 per share. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan entered on November 13, 2024, and Ross now directly holds 12,029 shares.
Kiniksa Pharmaceuticals, Ltd. Form 144 notice lists proposed sales of Class A ordinary shares tied to equity compensation and a restricted stock lapse. The excerpt shows a 04/07/2026 restricted-stock lapse and a proposed sale quantity listed as 79,513.00, plus a recent reported sale of 114,989.00 shares on 04/06/2026.